Tocilizumab Does Not Prevent Intubation, Death in COVID-19
THURSDAY, Oct. 22, 2020 -- For moderately ill hospitalized patients with COVID-19, tocilizumab is not effective for preventing intubation or death, according to a study published online Oct. 21 in the New England Journal of Medicine.
John H. Stone,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 22, 2020 Category: Pharmaceuticals Source Type: news
Study finds tocilizumab improves survival in critically ill patients with COVID-19
Researchers from 68 sites across the country, led by David E. Leaf, MD, MMSc and Shruti Gupta, MD, MPH from the Division of Renal Medicine at Brigham and Women's Hospital, have investigated the effects of the anti-inflammatory drug tocilizumab on critically ill patients with laboratory-confirmed COVID-19. Unlike steroids, which suppress the immune system more broadly, tocilizumab specifically inhibits the receptor for the pro-inflammatory cytokine, IL-6. (Source: World Pharma News)
Source: World Pharma News - October 21, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Tocilizumab doesn't ease symptoms or prevent death in moderately ill COVID-19 inpatients
(Massachusetts General Hospital) The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a study by researchers at Massachusetts General Hospital. The study, published in the New England Journal of Medicine, casts doubt on earlier research suggesting that tocilizumab, which is commonly prescribed for rheumatoid arthritis and other conditions, might be an effective treatment for patients with worsening cases of COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 21, 2020 Category: Infectious Diseases Source Type: news
New results from a once-promising therapy show the difficulty of treating covid-19
The drug, tocilizumab, showed early potential but evidence since then has been conflicting. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 20, 2020 Category: Consumer Health News Authors: Ben Guarino Source Type: news
Study: Tocilizumab reduces risk for death in hospitalized patients with severe COVID-19
Treatment with the rheumatoid arthritis drug tocilizumab, sold as Actemra, reduces risk for death among hospitalized patients with severe COVID-19 by about 30%, a study published Tuesday by JAMA Internal Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 20, 2020 Category: Consumer Health News Source Type: news
Efficacy of Tocilizumab in Patients With COVID-19 ARDS Efficacy of Tocilizumab in Patients With COVID-19 ARDS
How effective is tocilizumab therapy in patients who develop severe COVID-related ARDS?Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2020 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news
Examining association between early treatment with tocilizumab, risk of death among critically ill COVID-19 patients
(JAMA Network) Whether treatment with tocilizumab in the first two days after being admitted to an intensive care unit was associated with a reduced risk of death among critically ill patients with COVID-19 was investigated in this study. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news
Tocilizumab vs standard care on preventing worsening in patients hospitalized with COVID-19 pneumonia
(JAMA Network) Researchers in this randomized clinical trial compared the effect of early administration of tocilizumab with standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news
Effect of tocilizumab in adults hospitalized with COVID-19 with moderate or severe pneumonia
(JAMA Network) This randomized clinical trial assessed whether tocilizumab improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia compared to usual care. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news
Study finds tocilizumab improves survival in critically ill patients with COVID-19
(Brigham and Women's Hospital) The investigators found that when tocilizumab was administered within the first two days of intensive care unit (ICU) admission, there was a 30 percent relative decrease (and a 10 percent absolute decrease) in mortality compared to patients whose treatment did not include early use of tocilizumab. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 20, 2020 Category: Infectious Diseases Source Type: news
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
Government looks to review Tocilizumab inclusion for treatment, again
Tocilizumab,a rheumatoid arthritis drug, is part of the health ministry’s clinical management protocol for Covid-19 under investigational therapies for patients with moderate symptoms of the illness. (Source: The Economic Times)
Source: The Economic Times - September 23, 2020 Category: Consumer Health News Source Type: news
Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
